Candidates
Peptide candidates, as described in the sources
Different pages of the official site use different identifiers and indications. Each candidate is shown separately below, with its evidence level and any conflicting source noted. No stage is inferred.
JEL0305
- Indications described
- Atopic dermatitis; recurrence (hypothesis); skin ageing (hypothesis)
- Formulation
- Topical peptide with nanoparticle delivery; cream described
- Evidence described
- Company-reported cellular and human ex vivo biopsy results
- Status in reviewed sources
- Preclinical / ex vivo. No clinical phase established.
JEL3108
- Indications described
- Burns; post-operative scarring; scar prevention after tumour resection; exploratory lung adenocarcinoma cell research (2024 update)
- Formulation
- Topical / sterile spray concept (skin pages)
- Evidence described
- Historical preclinical descriptions; 2022 ethics permission for ex vivo tissue; company-reported lung cancer cell results
- Status in reviewed sources
- Research / preclinical. No clinical phase confirmed.
- Source note
- Scar prevention after tumour resection is distinct from treating cancer. The 2024 Boston Bootcamp article names JEL3108 for eczema, while current lead pages use JEL0305; the conflict is preserved.
JEL2603
- Indications described
- Inflammatory bowel disease
- Formulation
- Local gel concept
- Evidence described
- Description on the “other indications” page
- Status in reviewed sources
- Exploratory; current priority unconfirmed.
- Source note
- A legacy IBD page names JEL3108 for this indication instead. Mapping not resolved.
JEL1103
- Indications described
- Epidermolysis bullosa
- Formulation
- Topical concept
- Evidence described
- Description on the “other indications” page
- Status in reviewed sources
- Exploratory; current priority unconfirmed.
JEL3801
- Indications described
- Historical kinase-selectivity research
- Formulation
- —
- Evidence described
- Named in a selectivity paragraph of the 2022 ethics news
- Status in reviewed sources
- Historical research context; no current programme mapping confirmed.
The 2024 annual update also mentions two human dermatitis peptides, two cosmetic peptides and one animal dermatitis peptide, without mapping all identifiers.
Company development chart (February 2023)
No marketed drug or marketing approval is established by the reviewed sources. The 2022 HRA/HCRW/REC permission concerns ex vivo tissue research — not a drug approval or an administered clinical trial.